PL3473267T3 - Zindywidualizowane szczepionki przeciwnowotworowe - Google Patents

Zindywidualizowane szczepionki przeciwnowotworowe

Info

Publication number
PL3473267T3
PL3473267T3 PL18199105T PL18199105T PL3473267T3 PL 3473267 T3 PL3473267 T3 PL 3473267T3 PL 18199105 T PL18199105 T PL 18199105T PL 18199105 T PL18199105 T PL 18199105T PL 3473267 T3 PL3473267 T3 PL 3473267T3
Authority
PL
Poland
Prior art keywords
cancer
individualized vaccines
individualized
vaccines
Prior art date
Application number
PL18199105T
Other languages
English (en)
Inventor
Ugur Sahin
Sebastian Kreiter
Mustafa DIKEN
Jan DIEKMANN
Michael Koslowski
Cedrik Britten
John Castle
Martin LÖWER
Bernhard RENARD
Tana Omokoko
Johannes Hendrikus DE GRAAF
Original Assignee
BioNTech SE
Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg- Universität Mainz Gemeinnützige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50185364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3473267(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2011/002576 external-priority patent/WO2012159643A1/en
Application filed by BioNTech SE, Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg- Universität Mainz Gemeinnützige Gmbh filed Critical BioNTech SE
Priority claimed from PCT/EP2012/002209 external-priority patent/WO2012159754A2/en
Publication of PL3473267T3 publication Critical patent/PL3473267T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/40—Population genetics; Linkage disequilibrium
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Ecology (AREA)
  • Artificial Intelligence (AREA)
  • General Chemical & Material Sciences (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Evolutionary Computation (AREA)
PL18199105T 2011-05-24 2012-05-23 Zindywidualizowane szczepionki przeciwnowotworowe PL3473267T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2011/002576 WO2012159643A1 (en) 2011-05-24 2011-05-24 Individualized vaccines for cancer
EP2012000006 2012-01-02
EP12723117.3A EP2714071B1 (en) 2011-05-24 2012-05-23 Individualized vaccines for cancer
PCT/EP2012/002209 WO2012159754A2 (en) 2011-05-24 2012-05-23 Individualized vaccines for cancer
EP18199105.0A EP3473267B1 (en) 2011-05-24 2012-05-23 Individualized vaccines for cancer

Publications (1)

Publication Number Publication Date
PL3473267T3 true PL3473267T3 (pl) 2022-01-10

Family

ID=50185364

Family Applications (2)

Application Number Title Priority Date Filing Date
PL18199105T PL3473267T3 (pl) 2011-05-24 2012-05-23 Zindywidualizowane szczepionki przeciwnowotworowe
PL12723117T PL2714071T3 (pl) 2011-05-24 2012-05-23 Zindywidualizowane szczepionki przeciwrakowe

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL12723117T PL2714071T3 (pl) 2011-05-24 2012-05-23 Zindywidualizowane szczepionki przeciwrakowe

Country Status (9)

Country Link
EP (5) EP2714071B1 (pl)
CY (3) CY1122110T1 (pl)
DK (1) DK3473267T3 (pl)
HR (1) HRP20191535T1 (pl)
ME (1) ME03498B (pl)
PL (2) PL3473267T3 (pl)
RS (1) RS59369B1 (pl)
SI (1) SI2714071T1 (pl)
SM (1) SMT201900521T1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2714071T1 (sl) 2011-05-24 2019-11-29 Biontech Rna Pharmaceuticals Gmbh Individualizirana cepiva proti raku
LT2714071T (lt) 2011-05-24 2019-10-10 Biontech Rna Pharmaceuticals Gmbh Individualizuotos vakcinos nuo vėžio
CN108601820A (zh) * 2015-10-12 2018-09-28 南托米克斯有限责任公司 用于病毒癌症新表位的组合物和方法
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
CN113424264B (zh) * 2018-11-15 2024-04-12 Nouscom股份公司 用于生成个性化癌症疫苗的癌症突变选择
US20240240259A1 (en) * 2021-03-26 2024-07-18 The Translational Genomics Research Institute Methods and compounds for neoantigen vaccines

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP0871747A1 (en) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
WO1999034015A2 (en) 1997-12-24 1999-07-08 Imperial Cancer Research Technology Limited Polymorphisms within the rsk-3 gene related to cancer and methods of diagnosis, prognosis, and treatment
EP2100620A1 (en) * 1999-09-16 2009-09-16 Eisai Corporation of North America Nucleic acids encoding polyepitope polypeptides
ATE291925T1 (de) * 2001-06-05 2005-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
CN100392087C (zh) * 2001-11-26 2008-06-04 昆士兰大学 黄病毒疫苗输送系统
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
AU2003235707A1 (en) 2002-01-18 2003-07-30 Curevac Gmbh Immunogenic preparations and vaccines on the basis of mrna
AU2003229429A1 (en) 2002-05-07 2003-11-11 Aventis Pasteur, Ltd. Polyepitopes and mini-genes for cancer treatment
DE10335833A1 (de) * 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
IL158140A0 (en) 2003-09-25 2004-03-28 Hadasit Med Res Service Multiepitope polypeptides for cancer immunotherapy
DE102004035227A1 (de) 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US9115402B2 (en) * 2010-05-14 2015-08-25 Dana-Farber Cancer Institute, Inc. Compositions and methods of identifying tumor specific neoantigens
SI2714071T1 (sl) 2011-05-24 2019-11-29 Biontech Rna Pharmaceuticals Gmbh Individualizirana cepiva proti raku

Also Published As

Publication number Publication date
SMT201900521T1 (it) 2019-11-13
HRP20191535T1 (hr) 2019-11-29
EP3473267A1 (en) 2019-04-24
EP3892295B1 (en) 2023-04-26
EP2714071B1 (en) 2019-07-10
EP4223311A1 (en) 2023-08-09
EP4636774A2 (en) 2025-10-22
DK3473267T3 (da) 2021-10-18
ME03498B (me) 2020-04-20
EP4223311B1 (en) 2025-06-25
CY1126128T1 (el) 2023-11-15
EP4636774A3 (en) 2025-12-31
EP3473267B1 (en) 2021-09-08
CY1122110T1 (el) 2020-11-25
SI2714071T1 (sl) 2019-11-29
RS59369B1 (sr) 2019-11-29
PL2714071T3 (pl) 2019-12-31
EP3892295A1 (en) 2021-10-13
EP2714071A2 (en) 2014-04-09
CY1124685T1 (el) 2022-07-22

Similar Documents

Publication Publication Date Title
ZA201306944B (en) Individualized vaccines for cancer
SG11201400846PA (en) Adjustable fracturing system
IL231043A (en) vaccine
GB201120860D0 (en) Cancer immunotherapy
SG11201401632WA (en) Antigen presenting cancer vaccine
GB201119999D0 (en) Vaccine
SMT201900521T1 (it) Vaccini individualizzati per il cancro
ZA201306245B (en) Combination vaccines
SG2014007694A (en) Radiation source
PL2729158T3 (pl) Szczepionki przeciwko Chlamydia
GB201120000D0 (en) Vaccine
GB201106630D0 (en) Cancer therapy
GB201107549D0 (en) Cancer vaccine
GB201108984D0 (en) Vaccines
GB201108986D0 (en) Vaccines
GB201108982D0 (en) Vaccines
GB201108256D0 (en) Vaccine
GB201121647D0 (en) Vaccine
IL231330A0 (en) Cancer diagnosis methods
GB201118153D0 (en) Therapies for cancers
GB201116342D0 (en) Antigen combinations
GB201109294D0 (en) Novel vaccine